However, because our study was specifically designed to measure the risk of bladder cancer directly related to pioglitazone exposure, the results concerning use of other glucose-lowering therapies (oral or insulin) or other cancer sites should be interpreted with caution. Here, INS is linked to urinary bladder carcinoma.